Skip to content
value.today

Foresight Biotherapeutics, Inc.

🇺🇸 New York, New York, USABiotechnologyFounded 2008
Total raised
$17 M
2 rounds on record
Latest round
$15 M
Oct 2013
First round on record
Jul 2011
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Foresight Biotherapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2013$15 MNo. 2$10 to $50 million

Foresight Biotherapeutics, Inc.: Raise no. 2, Oct 2013

Investors in this round

2 investors had bought by the notice of Nov 13, 2013: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
$15,000,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jason Stein · Executive Officer, Director
  • Michael Weiser · Executive Officer, Director
  • Stephen Rocamboli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Weiser, Vice President. Source: SEC Form D, newest notice filed Nov 13, 2013. Read the notice at the SEC.

equity, optionsSEC
Jul 2011$2 MNo. 1$2 to $10 million

Foresight Biotherapeutics, Inc.: Raise no. 1, Jul 2011

Investors in this round

1 investor had bought by the notice of Jul 29, 2011: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$240,034
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jason Stein · Executive Officer, Director
  • Michael Weiser · Executive Officer, Director
  • Stephen Rocamboli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Weiser, Vice president. Source: SEC Form D, newest notice filed Jul 29, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Foresight Biotherapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2013).

    SEC Form D · Nov 2013

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2013

That is all the official record says: Foresight Biotherapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Foresight Biotherapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 2 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Foresight Biotherapeutics, Inc.
NameRoleNamed in
Jason SteinExecutive officerNov 2013
Michael WeiserExecutive officerNov 2013
Jason SteinDirectorNov 2013
Michael WeiserDirectorNov 2013
Stephen RocamboliDirectorNov 2013